198 related articles for article (PubMed ID: 17031555)
1. Local intracerebral administration of O(6)-benzylguanine combined with systemic chemotherapy with temozolomide of a patient suffering from a recurrent glioblastoma.
Koch D; Hundsberger T; Boor S; Kaina B
J Neurooncol; 2007 Mar; 82(1):85-9. PubMed ID: 17031555
[TBL] [Abstract][Full Text] [Related]
2. MGMT repletion after treatment of glioblastoma cells with temozolomide and O6-benzylguanine implicates NFκB and mutant p53.
Vlachostergios PJ; Hatzidaki E; Papandreou CN
Neurol Res; 2013 Oct; 35(8):879-82. PubMed ID: 23561593
[TBL] [Abstract][Full Text] [Related]
3. Multidrug Efflux Pumps Attenuate the Effect of MGMT Inhibitors.
Tomaszowski KH; Schirrmacher R; Kaina B
Mol Pharm; 2015 Nov; 12(11):3924-34. PubMed ID: 26379107
[TBL] [Abstract][Full Text] [Related]
4. MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial.
Weller M; Tabatabai G; Kästner B; Felsberg J; Steinbach JP; Wick A; Schnell O; Hau P; Herrlinger U; Sabel MC; Wirsching HG; Ketter R; Bähr O; Platten M; Tonn JC; Schlegel U; Marosi C; Goldbrunner R; Stupp R; Homicsko K; Pichler J; Nikkhah G; Meixensberger J; Vajkoczy P; Kollias S; Hüsing J; Reifenberger G; Wick W;
Clin Cancer Res; 2015 May; 21(9):2057-64. PubMed ID: 25655102
[TBL] [Abstract][Full Text] [Related]
5. Temozolomide Resistance in Glioblastoma Cell Lines: Implication of MGMT, MMR, P-Glycoprotein and CD133 Expression.
Perazzoli G; Prados J; Ortiz R; Caba O; Cabeza L; Berdasco M; Gónzalez B; Melguizo C
PLoS One; 2015; 10(10):e0140131. PubMed ID: 26447477
[TBL] [Abstract][Full Text] [Related]
6. Lipoic acid inhibits the DNA repair protein O 6-methylguanine-DNA methyltransferase (MGMT) and triggers its depletion in colorectal cancer cells with concomitant autophagy induction.
Göder A; Nagel G; Kraus A; Dörsam B; Seiwert N; Kaina B; Fahrer J
Carcinogenesis; 2015 Aug; 36(8):817-31. PubMed ID: 25998848
[TBL] [Abstract][Full Text] [Related]
7. MGMT-inhibitor in combination with TGF-βRI inhibitor or CDK 4/6 inhibitor increases temozolomide sensitivity in temozolomide-resistant glioblastoma cells.
Das A; Henderson FC; Alshareef M; Porto GBF; Kanginakudru I; Infinger LK; Vandergrift WA; Lindhorst SM; Varma AK; Patel SJ; Cachia D
Clin Transl Oncol; 2021 Mar; 23(3):612-619. PubMed ID: 32710211
[TBL] [Abstract][Full Text] [Related]
8. MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma.
Donson AM; Addo-Yobo SO; Handler MH; Gore L; Foreman NK
Pediatr Blood Cancer; 2007 Apr; 48(4):403-7. PubMed ID: 16609952
[TBL] [Abstract][Full Text] [Related]
9. DNA-Targeted Inhibition of MGMT.
Marsoner T; Schmidt OP; Triemer T; Luedtke NW
Chembiochem; 2017 May; 18(10):894-898. PubMed ID: 28177192
[TBL] [Abstract][Full Text] [Related]
10. Acridine-O
Franco Pinto J; Fillion A; Duchambon P; Bombard S; Granzhan A
Eur J Med Chem; 2022 Jan; 227():113909. PubMed ID: 34731767
[TBL] [Abstract][Full Text] [Related]
11. MiR-198 enhances temozolomide sensitivity in glioblastoma by targeting MGMT.
Nie E; Jin X; Wu W; Yu T; Zhou X; Shi Z; Zhang J; Liu N; You Y
J Neurooncol; 2017 May; 133(1):59-68. PubMed ID: 28425046
[TBL] [Abstract][Full Text] [Related]
12. Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment.
Cahill DP; Levine KK; Betensky RA; Codd PJ; Romany CA; Reavie LB; Batchelor TT; Futreal PA; Stratton MR; Curry WT; Iafrate AJ; Louis DN
Clin Cancer Res; 2007 Apr; 13(7):2038-45. PubMed ID: 17404084
[TBL] [Abstract][Full Text] [Related]
13. The MGMT promoter SNP rs16906252 is a risk factor for MGMT methylation in glioblastoma and is predictive of response to temozolomide.
Rapkins RW; Wang F; Nguyen HN; Cloughesy TF; Lai A; Ha W; Nowak AK; Hitchins MP; McDonald KL
Neuro Oncol; 2015 Dec; 17(12):1589-98. PubMed ID: 25910840
[TBL] [Abstract][Full Text] [Related]
14. Targeting methylguanine-DNA methyltransferase in the treatment of neuroblastoma.
Wagner LM; McLendon RE; Yoon KJ; Weiss BD; Billups CA; Danks MK
Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5418-25. PubMed ID: 17875772
[TBL] [Abstract][Full Text] [Related]
15. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
[TBL] [Abstract][Full Text] [Related]
16. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients.
Brandes AA; Franceschi E; Tosoni A; Blatt V; Pession A; Tallini G; Bertorelle R; Bartolini S; Calbucci F; Andreoli A; Frezza G; Leonardi M; Spagnolli F; Ermani M
J Clin Oncol; 2008 May; 26(13):2192-7. PubMed ID: 18445844
[TBL] [Abstract][Full Text] [Related]
17. Sensitization of pancreatic tumor xenografts to carmustine and temozolomide by inactivation of their O6-Methylguanine-DNA methyltransferase with O6-benzylguanine or O6-benzyl-2'-deoxyguanosine.
Kokkinakis DM; Ahmed MM; Chendil D; Moschel RC; Pegg AE
Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3801-7. PubMed ID: 14506174
[TBL] [Abstract][Full Text] [Related]
18. MGMT in primary and recurrent human glioblastomas after radiation and chemotherapy and comparison with p53 status and clinical outcome.
Wiewrodt D; Nagel G; Dreimüller N; Hundsberger T; Perneczky A; Kaina B
Int J Cancer; 2008 Mar; 122(6):1391-9. PubMed ID: 18000822
[TBL] [Abstract][Full Text] [Related]
19. Chemotherapy sensitization of glioblastoma by focused ultrasound-mediated delivery of therapeutic liposomes.
Papachristodoulou A; Signorell RD; Werner B; Brambilla D; Luciani P; Cavusoglu M; Grandjean J; Silginer M; Rudin M; Martin E; Weller M; Roth P; Leroux JC
J Control Release; 2019 Feb; 295():130-139. PubMed ID: 30537486
[TBL] [Abstract][Full Text] [Related]
20. Endoplasmic reticulum stress-inducing drugs sensitize glioma cells to temozolomide through downregulation of MGMT, MPG, and Rad51.
Xipell E; Aragón T; Martínez-Velez N; Vera B; Idoate MA; Martínez-Irujo JJ; Garzón AG; Gonzalez-Huarriz M; Acanda AM; Jones C; Lang FF; Fueyo J; Gomez-Manzano C; Alonso MM
Neuro Oncol; 2016 Aug; 18(8):1109-19. PubMed ID: 26951384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
